Enliven Therapeutics Inc

Enliven Therapeutics’ latest 10b5‑1 sale shows routine COO trading, while Phase II data for its pancreatic cancer drug and orphan‑drug status drive investor excitement and a near‑50% weekly rise in shares.

Enliven Therapeutics insider trades show routine liquidity, not loss of confidence; the firm’s kinase‑inhibitor pipeline and neutral market sentiment suggest a buy‑or‑hold for long‑term investors.

Insider buying fuels optimism for Enliven Therapeutics after Phase 1b success; investors eye potential upside amid high‑growth biotech volatility.